Edwards Lifesciences [EW] vs Dexcom [DXCM] Detailed Stock Comparison

Edwards Lifesciences Corporation

NYSE
Loading...

Dexcom Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Edwards Lifesciences Corporation wins in 10 metrics, Dexcom Inc. wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Edwards Lifesciences Corporation Dexcom Inc. Better
P/E Ratio (TTM) 46.49 30.03 Dexcom Inc.
Price-to-Book Ratio 4.73 8.63 Edwards Lifesciences Corporation
Debt-to-Equity Ratio 6.82 50.85 Edwards Lifesciences Corporation
PEG Ratio -0.62 0.39 Dexcom Inc.
EV/EBITDA 23.85 19.85 Dexcom Inc.
Profit Margin (TTM) 17.39% 17.94% Dexcom Inc.
Operating Margin (TTM) 31.22% 25.64% Edwards Lifesciences Corporation
EBITDA Margin (TTM) 31.22% 25.64% Edwards Lifesciences Corporation
Return on Equity 10.38% 34.50% Dexcom Inc.
Return on Assets (TTM) 7.84% 8.89% Dexcom Inc.
Free Cash Flow (TTM) $1.34B $1.08B Edwards Lifesciences Corporation
1-Year Return 13.25% -8.07% Edwards Lifesciences Corporation
Price-to-Sales Ratio (TTM) 7.70 5.10 Dexcom Inc.
Enterprise Value $45.35B $23.09B Edwards Lifesciences Corporation
EV/Revenue Ratio 7.20 4.95 Dexcom Inc.
Gross Profit Margin (TTM) 78.15% 62.93% Edwards Lifesciences Corporation
Revenue per Share (TTM) $11 $12 Dexcom Inc.
Earnings per Share (Diluted) $1.81 $2.05 Dexcom Inc.
Beta (Stock Volatility) 0.95 1.56 Edwards Lifesciences Corporation
Short % of Float 1.84% 4.93% Edwards Lifesciences Corporation

Edwards Lifesciences Corporation vs Dexcom Inc. Stock Performance Analysis

Loading Price Chart...

EW
DXCM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Edwards Lifesciences Corporation1.37%0.50%6.02%3.26%3.48%1.11%
Dexcom Inc.-1.53%-3.13%20.43%11.88%12.92%11.54%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Edwards Lifesciences Corporation13.25%-7.43%-15.49%159.09%507.93%2,151.59%
Dexcom Inc.-8.07%-42.07%-27.92%315.26%2,149.85%2,129.88%

Performance & Financial Health Analysis: Edwards Lifesciences Corporation vs Dexcom Inc.

MetricEWDXCM
Market Information
Market Cap i$48.52B$23.76B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,242,6504,652,604
90 Day Avg. Volume i5,032,2704,100,848
Last Close$86.28$74.22
52 Week Range$72.30 - $89.48$54.11 - $89.98
% from 52W High-3.58%-17.52%
All-Time High$131.73 (Dec 27, 2021)$164.86 (Nov 15, 2021)
% from All-Time High-34.50%-54.98%
Growth Metrics
Quarterly Revenue Growth0.17%0.13%
Quarterly Earnings Growth0.06%0.76%
Financial Health
Profit Margin (TTM) i0.17%0.18%
Operating Margin (TTM) i0.31%0.26%
Return on Equity (TTM) i0.10%0.35%
Debt to Equity (MRQ) i6.8250.85
Cash & Liquidity
Book Value per Share (MRQ)$17.80$7.14
Cash per Share (MRQ)$7.28$5.19
Operating Cash Flow (TTM) i$1.50B$1.44B
Levered Free Cash Flow (TTM) i$1.07B$719.54M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Edwards Lifesciences Corporation vs Dexcom Inc.

MetricEW (Apr 26, 2026)DXCM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i46.4930.03
Forward P/E i25.0520.59
PEG Ratio i-0.620.39
Price to Sales (TTM) i7.705.10
Price to Book (MRQ) i4.738.63
Market Capitalization
Market Capitalization i$48.52B$23.76B
Enterprise Value i$45.35B$23.09B
Enterprise Value Metrics
Enterprise to Revenue i7.204.95
Enterprise to EBITDA i23.8519.85
Risk & Other Metrics
Beta i0.951.56
Book Value per Share (MRQ) i$17.80$7.14

Financial Statements Comparison: Edwards Lifesciences Corporation vs Dexcom Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricEW (2025)DXCM (2025)
Revenue/Sales i6.07B4.66B
Cost of Goods Sold i1.33B1.86B
COGS % of Revenue i22.0%39.9%
Gross Profit i4.73B2.80B
Gross Margin i78.0%60.1%
Research & Development i1.08B599.10M
Operating Income (EBIT) i1.64B911.80M
Operating Margin i27.0%19.6%
EBITDA i1.96B1.36B
EBITDA Margin i32.4%29.1%
Pre-Tax Income i1.27B1.09B
Pre-Tax Income % of Revenue i21.0%23.3%
Income Tax i216.90M252.10M
Income Tax % of Revenue i3.6%5.4%
Net Income (Profit) i1.07B836.30M
Profit Margin i17.6%17.9%

Balance Sheet & Liquidity Metrics

MetricEW (2025)DXCM (2025)
Cash & Equivalents i2.94B917.70M
Total Current Assets i6.74B4.03B
Total Current Assets % of Revenue i111.1%86.5%
Total Current Liabilities i1.81B2.14B
Total Current Liabilities % of Revenue i29.9%46.0%
Long-Term Debt i680.90M1.37B
Long-Term Debt % of Revenue i11.2%29.3%
Total Shareholders Equity i10.34B2.75B
Retained Earnings i14.24B2.43B
Retained Earnings % of Revenue i234.7%52.2%
Property, Plant & Equipment i102.70M77.40M

Cash Flow Statement Comparison

MetricEW (2025)DXCM (2025)
Operating Cash Flow i1.50B1.48B
Operating Cash Flow % of Revenue i24.7%31.7%
Capital Expenditures iN/A-363.50M
Free Cash Flow i1.34B1.08B
FCF Margin i22.0%23.1%
Debt Repayment iN/A-1.21B
Common Stock Repurchase i-893.40M-500.00M

Short Interest & Institutional Ownership Analysis

MetricEWDXCM
Shares Short i9.33M14.72M
Short Ratio i2.053.77
Short % of Float i1.84%4.93%
Shares Outstanding i580.70M384.80M
Float Shares i579.02M382.94M
% Held by Insiders i0.17%0.28%
% Held by Institutions i92.88%101.50%
% Held by Public i6.95%-1.78%

Dividend Analysis & Yield Comparison: Edwards Lifesciences Corporation vs Dexcom Inc.

MetricEWDXCM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A